Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2020-10-19 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo Biopharma Group PLC, with the SEC. It includes a press release dated October 19, 2020, but the text does not contain detailed financial statements or substantive financial data. The document length is only 1369 characters, which is quite short and typical for a regulatory announcement rather than a full report. The Form 6-K is used for current reports by foreign private issuers to disclose material information. Given the short length and the nature of the content (a press release), this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often includes Form 6-K filings.
2020-10-19 English
TIGIT IND FDA Clearance
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement distributed via the London Stock Exchange's RNS (Regulatory News Service). It details a specific corporate update regarding FDA clearance for a clinical trial (etigilimab). While it contains forward-looking statements and business updates, it does not constitute a formal financial report (like a 10-K or IR), a transcript, or a presentation. As it is a general regulatory announcement regarding company operations that does not fit into more specific categories like M&A or dividend notices, it is classified as a Regulatory Filing (RNS).
2020-10-19 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo Biopharma Group PLC, pursuant to SEC rules. It references a Regulatory News Service Announcement as an exhibit and is dated October 2020. The document length is only 1414 characters, which is quite short and does not contain detailed financial data or substantive report content. It appears to be a regulatory filing providing an update or announcement rather than a full report such as an annual or interim report. According to the rules, Form 6-K filings that are brief and serve as announcements or updates fall under Regulatory Filings (RNS).
2020-10-13 English
PDMR Notification
Director's Dealing Classification · 100% confidence The document is a notification of a share purchase by a Person Discharging Managerial Responsibilities (PDMR), specifically the General Counsel, Charles Sermon. It explicitly references the EU Market Abuse Regulation and provides the required disclosure details for an insider transaction. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2020-10-12 English
Regulatory Filings 2020
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or fiscal period dates that would allow identification of a specific filing type. There is no indication of report titles, financial data, or announcements. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS). The confidence is moderate due to the inability to extract meaningful content.
2020-10-09 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo Biopharma Group PLC, pursuant to SEC rules. It references a Regulatory News Service Announcement dated October 9, 2020, but does not contain substantive financial data or detailed report content itself. The document length is only 1412 characters, indicating it is a short filing likely serving as a regulatory announcement rather than a full report. According to the rules, such short filings that announce or attach other reports without containing the report itself should be classified as Regulatory Filings (RNS).
2020-10-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.